{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T04:31:37Z","timestamp":1783744297304,"version":"3.55.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-025-04070-z","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T10:22:36Z","timestamp":1762165356000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["HROB is a novel prognostic biomarker correlated with immune cell infiltration and tumor progression in lung adenocarcinoma"],"prefix":"10.1186","volume":"23","author":[{"given":"Yongjie","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoqiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingxue","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuotao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honglin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye jun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"issue":"3","key":"4070_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"4070_CR2","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/nrc3775","volume":"14","author":"Z Chen","year":"2014","unstructured":"Chen Z, Fillmore CM, Hammerman PS, et al. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014;14(8):535\u201346.","journal-title":"Nat Rev Cancer"},{"key":"4070_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2024.102315","volume":"97","author":"SK Jha","year":"2024","unstructured":"Jha SK, DE Rubis G, Devkota SR, et al. Cellular senescence in lung cancer: molecular mechanisms and therapeutic interventions. Ageing Res Rev. 2024;97:102315.","journal-title":"Ageing Res Rev"},{"issue":"6","key":"4070_CR4","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.cell.2012.08.029","volume":"150","author":"M Imielinski","year":"2012","unstructured":"Imielinski M, Berger AH, Hammerman PS, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 2012;150(6):1107\u201320.","journal-title":"Cell"},{"issue":"1","key":"4070_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-47767-5","volume":"13","author":"H Pasternack","year":"2023","unstructured":"Pasternack H, Polzer M, Gemoll T, et al. Proteomic analyses identify HK1 and ATP5A to be overexpressed in distant metastases of lung adenocarcinomas compared to matched primary tumors. Sci Rep. 2023;13(1):20948.","journal-title":"Sci Rep"},{"issue":"17","key":"4070_CR6","doi-asserted-by":"publisher","first-page":"13618","DOI":"10.3390\/ijms241713618","volume":"24","author":"HY Choi","year":"2023","unstructured":"Choi HY, Chang JE. Targeted Therapy for Cancers: From Ongoing Clinical Trials to FDA-Approved Drugs. Int J Mol Sci. 2023;24(17):13618. https:\/\/doi.org\/10.3390\/ijms241713618.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"4070_CR7","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/s41417-024-00761-z","volume":"31","author":"H Liang","year":"2024","unstructured":"Liang H, Xu Y, Zhao J, et al. Hippo pathway in non-small cell lung cancer: mechanisms, potential targets, and biomarkers. Cancer Gene Ther. 2024;31(5):652\u201366.","journal-title":"Cancer Gene Ther"},{"issue":"1","key":"4070_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47936-8","volume":"15","author":"A Acharya","year":"2024","unstructured":"Acharya A, Bret H, Huang JW, et al. Mechanism of DNA unwinding by MCM8-9 in complex with HROB. Nat Commun. 2024;15(1):3584.","journal-title":"Nat Commun"},{"issue":"19\u201320","key":"4070_CR9","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1101\/gad.331850.119","volume":"33","author":"G Saredi","year":"2019","unstructured":"Saredi G, Rouse J. Ways to unwind with HROB, a new player in homologous recombination. Genes Dev. 2019;33(19\u201320):1293\u20134.","journal-title":"Genes Dev"},{"issue":"19\u201320","key":"4070_CR10","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1101\/gad.329508.119","volume":"33","author":"N Hustedt","year":"2019","unstructured":"Hustedt N, Saito Y, Zimmermann M, et al. Control of homologous recombination by the HROB-MCM8-MCM9 pathway. Genes Dev. 2019;33(19\u201320):1397\u2013415.","journal-title":"Genes Dev"},{"key":"4070_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.dnarep.2020.102946","volume":"95","author":"C Wang","year":"2020","unstructured":"Wang C, Chen Z. C17orf53 is identified as a novel gene involved in inter-strand crosslink repair. DNA Repair (Amst). 2020;95:102946.","journal-title":"DNA Repair (Amst)"},{"issue":"2","key":"4070_CR12","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41431-021-00977-9","volume":"30","author":"G TUCKER E J, BELL K M, ROBEVSKA","year":"2022","unstructured":"Tucker E J, Bell K M, Robevska G, et al. Meiotic genes in premature ovarian insufficiency: variants in HROB and REC8 as likely genetic causes [J]. Eur J Hum Genet. 2022;30(2):219\u201328.","journal-title":"Eur J Hum Genet"},{"issue":"1","key":"4070_CR13","doi-asserted-by":"publisher","first-page":"2948","DOI":"10.1038\/s41467-020-16718-3","volume":"11","author":"JW HUANG","year":"2020","unstructured":"Huang JW, Acharya A, Taglialatela A, et al. MCM8IP activates the MCM8-9 helicase to promote DNA synthesis and homologous recombination upon DNA damage [J]. Nat Commun. 2020;11(1):2948.","journal-title":"Nat Commun"},{"issue":"3","key":"4070_CR14","first-page":"564","volume":"170","author":"A TSHERNIAK","year":"2017","unstructured":"Tsherniak A, Vazquez F, Montgomery P G, et al. Defining Cancer Dependency Map [J] Cell. 2017;170(3):564\u2013e7616.","journal-title":"Defining Cancer Dependency Map [J] Cell"},{"issue":"2","key":"4070_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.crmeth.2022.100171","volume":"2","author":"PP Strybol","year":"2022","unstructured":"Strybol PP, Larmuseau M, De Schaetzen Van Brienen L, et al. Extracting functional insights from loss-of-function screens using deep link prediction. Cell Rep Methods. 2022;2(2):100171.","journal-title":"Cell Rep Methods"},{"issue":"W1","key":"4070_CR16","doi-asserted-by":"publisher","first-page":"W98","DOI":"10.1093\/nar\/gkx247","volume":"45","author":"Z Tang","year":"2017","unstructured":"Tang Z, Li C. Gepia: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98-102.","journal-title":"Nucleic Acids Res"},{"issue":"11","key":"4070_CR17","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/nri3902","volume":"15","author":"SJ TURLEY","year":"2015","unstructured":"Turley SJ, Astarita Cremascov. Immunological hallmarks of stromal cells in the tumour microenvironment [J]. Nat Rev Immunol. 2015;15(11):669\u201382.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"4070_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01428-1","volume":"20","author":"X Mao","year":"2021","unstructured":"Mao X, Xu J, Wang W, et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer. 2021;20(1):131.","journal-title":"Mol Cancer"},{"key":"4070_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jnutbio.2024.109647","volume":"130","author":"M Ashrafizadeh","year":"2024","unstructured":"Ashrafizadeh M, Aref AR, Sethi G, et al. Natural product\/diet-based regulation of macrophage polarization: implications in treatment of inflammatory-related diseases and cancer. J Nutr Biochem. 2024;130:109647.","journal-title":"J Nutr Biochem"},{"key":"4070_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara K, Shahmoradgoli M, MART\u00edNEZ E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.","journal-title":"Nat Commun"},{"key":"4070_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4NZELMANN","year":"2013","unstructured":"H\u00e4NZELMANN S, Castelo R. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013;14:7.","journal-title":"BMC Bioinformatics"},{"issue":"W1","key":"4070_CR22","doi-asserted-by":"publisher","first-page":"W509","DOI":"10.1093\/nar\/gkaa407","volume":"48","author":"T LI","year":"2020","unstructured":"Li T, Fu J, Zeng Z, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells [J]. Nucleic Acids Res. 2020;48(W1):W509\u201314.","journal-title":"Nucleic Acids Res"},{"issue":"12","key":"4070_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.","journal-title":"Genome Biol"},{"issue":"5","key":"4070_CR24","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, Wang LG, Han Y, et al. ClusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284\u20137.","journal-title":"OMICS"},{"issue":"D1","key":"4070_CR25","doi-asserted-by":"publisher","first-page":"D605","DOI":"10.1093\/nar\/gkaa1074","volume":"49","author":"SZKLARCZYKD GABLE A L","year":"2021","unstructured":"Gable A L Szklarczykd, Nastou K C, et al. The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene\/measurement sets [J]. Nucleic Acids Res. 2021;49(D1):D605\u201312.","journal-title":"Nucleic Acids Res"},{"issue":"11","key":"4070_CR26","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"P Shannon","year":"2003","unstructured":"Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498\u2013504.","journal-title":"Genome Res"},{"issue":"1","key":"4070_CR27","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13568-024-01691-7","volume":"14","author":"C LIU","year":"2024","unstructured":"Liu C, Li X. Identification of hub genes and establishment of a diagnostic model in tuberculosis infection [J]. AMB Express. 2024;14(1):36.","journal-title":"AMB Express"},{"key":"4070_CR28","doi-asserted-by":"publisher","DOI":"10.1126\/science.aal3321","author":"PJ Thul","year":"2017","unstructured":"Thul PJ, \u00c5kesson L, Wiking M, et al. A subcellular map of the human proteome. Science. 2017. https:\/\/doi.org\/10.1126\/science.aal3321.","journal-title":"Science"},{"issue":"2","key":"4070_CR29","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41591-022-02163-w","volume":"29","author":"N Niknafs","year":"2023","unstructured":"Niknafs N, Balan A, Cherry C, et al. Persistent mutation burden drives sustained anti-tumor immune responses. Nat Med. 2023;29(2):440\u20139.","journal-title":"Nat Med"},{"issue":"2","key":"4070_CR30","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ccell.2020.10.001","volume":"39","author":"DL Jardim","year":"2021","unstructured":"Jardim DL, Goodman A, DE Melo Gagliato D, et al. The challenges of tumor mutational burden as an immunotherapy biomarker. Cancer Cell. 2021;39(2):154\u201373.","journal-title":"Cancer Cell"},{"issue":"1","key":"4070_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11580-0","volume":"23","author":"S Li","year":"2023","unstructured":"Li S, Wang W. Characterization of genomic instability-related genes predicts survival and therapeutic response in lung adenocarcinoma. BMC Cancer. 2023;23(1):1115.","journal-title":"BMC Cancer"},{"key":"4070_CR32","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1146\/annurev.biochem.73.011303.073723","volume":"73","author":"A Sancar","year":"2004","unstructured":"Sancar A, Lindsey-Boltz LA, UNSAL-KA\u00e7MAZ K, et al. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem. 2004;73:39\u201385.","journal-title":"Annu Rev Biochem"},{"issue":"1","key":"4070_CR33","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12943-023-01801-2","volume":"22","author":"Y WU","year":"2023","unstructured":"Wu Y, Song Y, Wang R, et al. Molecular mechanisms of tumor resistance to radiotherapy [J]. Mol Cancer. 2023;22(1):96.","journal-title":"Mol Cancer"},{"key":"4070_CR34","doi-asserted-by":"publisher","first-page":"904060","DOI":"10.3389\/fgene.2022.904060","volume":"13","author":"X LIU","year":"2022","unstructured":"Liu X. Pan-Cancer analysis identified homologous recombination factor with OB-Fold (HROB) as a potential biomarker for various tumor types [J]. Front Genet. 2022;13:904060.","journal-title":"Front Genet"},{"issue":"12","key":"4070_CR35","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1038\/s41590-023-01678-9","volume":"24","author":"LA Walsh","year":"2023","unstructured":"Walsh LA, Quail DF. Decoding the tumor microenvironment with spatial technologies. Nat Immunol. 2023;24(12):1982\u201393.","journal-title":"Nat Immunol"},{"issue":"1","key":"4070_CR36","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1186\/s12967-024-05134-6","volume":"22","author":"Y CHEN","year":"2024","unstructured":"Chen Y, Yu D, Qian H, et al. CD8\u2009+\u2009T cell-based cancer immunotherapy [J]. J Translational Med. 2024;22(1):394.","journal-title":"J Translational Med"},{"issue":"3","key":"4070_CR37","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.3390\/ijms23031833","volume":"23","author":"ZLZ Hay","year":"2022","unstructured":"Hay ZLZ, Slansky JE. Granzymes: The Molecular Executors of Immune-Mediated Cytotoxicity. Int J Mol Sci. 2022;23(3):1833. https:\/\/doi.org\/10.3390\/ijms23031833.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"4070_CR38","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/j.immuni.2020.04.005","volume":"52","author":"C BOSTEELS","year":"2020","unstructured":"Bosteels C, Neyt K, Vanheerswynghels M, et al. Inflammatory type 2 cDCs acquire features of cDC1s and macrophages to orchestrate immunity to respiratory virus infection [J]. Immunity. 2020;52(6):1039\u2013e569.","journal-title":"Immunity"},{"key":"4070_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.669474","volume":"12","author":"A Basu","year":"2021","unstructured":"Basu A, Ramamoorthi G, Albert G, et al. Differentiation and regulation of t(h) cells: a balancing act for cancer immunotherapy. Front Immunol. 2021;12:669474.","journal-title":"Front Immunol"},{"issue":"9","key":"4070_CR40","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1172\/JCI80007","volume":"125","author":"S SHALAPOUR","year":"2015","unstructured":"Shalapour S. Immunity, inflammation, and cancer: an eternal fight between good and evil [J]. J Clin Invest. 2015;125(9):3347\u201355.","journal-title":"J Clin Invest"},{"issue":"5","key":"4070_CR41","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.immuni.2010.05.007","volume":"32","author":"S Gordon","year":"2010","unstructured":"Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions. Immunity. 2010;32(5):593\u2013604.","journal-title":"Immunity"},{"issue":"10","key":"4070_CR42","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/nrc2723","volume":"9","author":"ORENM LEVINE A J","year":"2009","unstructured":"Levine A J Orenm. The first 30 years of p53: growing ever more complex [J]. Nat Rev Cancer. 2009;9(10):749\u201358.","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"4070_CR43","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1080\/14737140.2021.1908132","volume":"21","author":"J Chen","year":"2021","unstructured":"Chen J, Liao Y, Fan X. Prognostic and clinicopathological value of BUB1B expression in patients with lung adenocarcinoma: a meta-analysis. Expert Rev Anticancer Ther. 2021;21(7):795\u2013803.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"358","key":"4070_CR44","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.2005379","volume":"8","author":"S Nyati","year":"2015","unstructured":"Nyati S, Schinske-Sebolt K, Pitchiaya S, et al. The kinase activity of the Ser\/Thr kinase BUB1 promotes TGF-\u03b2 signaling. Sci Signal. 2015;8(358):ra1.","journal-title":"Sci Signal"},{"issue":"1","key":"4070_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-42801-y","volume":"13","author":"P Dai","year":"2023","unstructured":"Dai P, Xiong L, Wei Y, et al. A pancancer analysis of the oncogenic role of Cyclin B1 (CCNB1) in human tumors. Sci Rep. 2023;13(1):16226.","journal-title":"Sci Rep"},{"issue":"6","key":"4070_CR46","doi-asserted-by":"publisher","first-page":"e16789","DOI":"10.1016\/j.heliyon.2023.e16789","volume":"9","author":"H SONG","year":"2023","unstructured":"Song H, Wu J, Liu W, et al. Key genes involved with prognosis were identified in lung adenocarcinoma by integrated bioinformatics analysis [J]. Heliyon. 2023;9(6):e16789.","journal-title":"Heliyon"},{"key":"4070_CR47","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.bbrc.2023.08.039","volume":"678","author":"Y Sakuma","year":"2023","unstructured":"Sakuma Y, Hirai S, Sumi T, et al. Dual inhibition of KIF11 and BCL2L1 induces apoptosis in lung adenocarcinoma cells. Biochem Biophys Res Commun. 2023;678:84\u20139.","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"4070_CR48","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1080\/10408363.2024.2309933","volume":"61","author":"NN Kreis","year":"2024","unstructured":"Kreis NN, Moon HH, Wordeman L, et al. KIF2C\/MCAK a prognostic biomarker and its oncogenic potential in malignant progression, and prognosis of cancer patients: a systematic review and meta-analysis as biomarker. Crit Rev Clin Lab Sci. 2024;61(6):404\u201334. https:\/\/doi.org\/10.1080\/10408363.2024.2309933.","journal-title":"Crit Rev Clin Lab Sci"},{"key":"4070_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.122437","volume":"340","author":"L Wang","year":"2024","unstructured":"Wang L, Zhang H, Li Y, et al. TPX2 influences the regulation of macrophage polarization via the NF-\u03baB pathway in lung adenocarcinoma. Life Sci. 2024;340:122437.","journal-title":"Life Sci"},{"issue":"3","key":"4070_CR50","first-page":"2563","volume":"16","author":"M ZHU","year":"2024","unstructured":"Zhu M, Wang X, Zhang Q, et al. Integrative analysis confirms TPX2 as a novel biomarker for clinical implication, tumor microenvironment, and immunotherapy response across human solid tumors [J]. Aging. 2024;16(3):2563\u201390.","journal-title":"Aging"},{"issue":"1","key":"4070_CR51","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s12967-024-04910-8","volume":"22","author":"M CHEN","year":"2024","unstructured":"Chen M, Zhang S, Wang F, et al. DLGAP5 promotes lung adenocarcinoma growth via upregulating PLK1 and serves as a therapeutic target [J]. J Transl Med. 2024;22(1):209.","journal-title":"J Transl Med"},{"key":"4070_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2021.153459","volume":"223","author":"C Hu","year":"2021","unstructured":"Hu C, Wu J, Wang L, et al. MiR-133b inhibits cell proliferation, migration, and invasion of lung adenocarcinoma by targeting CDCA8. Pathol Res Pract. 2021;223:153459.","journal-title":"Pathol Res Pract"},{"issue":"5","key":"4070_CR53","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/s43018-020-0066-y","volume":"1","author":"E Ghorani","year":"2020","unstructured":"Ghorani E, Reading JL, Henry JY, et al. The T cell differentiation landscape is shaped by tumour mutations in lung cancer. Nat Cancer. 2020;1(5):546\u201361.","journal-title":"Nat Cancer"},{"key":"4070_CR54","doi-asserted-by":"publisher","first-page":"731798","DOI":"10.3389\/fphar.2021.731798","volume":"12","author":"J LIU","year":"2021","unstructured":"Liu J, Chen Z, LI Y, et al. PD-1\/PD-L1 checkpoint inhibitors in tumor immunotherapy [J]. Front Pharmacol. 2021;12:731798.","journal-title":"Front Pharmacol"},{"issue":"5","key":"4070_CR55","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","volume":"44","author":"KUCHROOVK ANDERSON A C, JOLLER N","year":"2016","unstructured":"Anderson A C, Joller N Kuchroovk, Lag-3. Tim-3, and TIGIT: Co-inhibitory receptors with specialized functions in immune regulation [J]. Immunity. 2016;44(5):989\u20131004.","journal-title":"Immunity"},{"issue":"6","key":"4070_CR56","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nrc2639","volume":"9","author":"S L\u00f6B","year":"2009","unstructured":"L\u00f6B S, K\u00f6nigsrainer A, Rammensee H G, et al. Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? [J]. Nat Rev Cancer. 2009;9(6):445\u201352.","journal-title":"Nat Rev Cancer"},{"key":"4070_CR57","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","volume":"740","author":"S DASARI","year":"2014","unstructured":"Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action [J]. Eur J Pharmacol. 2014;740:364\u201378.","journal-title":"Eur J Pharmacol"},{"issue":"18","key":"4070_CR58","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1091\/mbc.e14-04-0916","volume":"25","author":"BA WEAVER","year":"2014","unstructured":"Weaver BA. How Taxol\/paclitaxel kills cancer cells [J]. Mol Biol Cell. 2014;25(18):2677\u201381.","journal-title":"Mol Biol Cell"},{"issue":"10","key":"4070_CR59","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/nrd3253","volume":"9","author":"C DUMONTET","year":"2010","unstructured":"Dumontet C, Jordan MA. Microtubule-binding agents: a dynamic field of cancer therapeutics [J]. Nat Rev Drug Discov. 2010;9(10):790\u2013803.","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"4070_CR60","doi-asserted-by":"publisher","first-page":"291","DOI":"10.2217\/fon-2022-0842","volume":"19","author":"JC YANG","year":"2023","unstructured":"Yang JC. Afatinib for the treatment of non-small-cell lung cancer with unusual EGFR mutations: a plain Language summary [J]. Future Oncol. 2023;19(4):291\u20137.","journal-title":"Future Oncol"},{"issue":"1","key":"4070_CR61","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s41392-022-01286-3","volume":"8","author":"ZHONG W Z","year":"2023","unstructured":"Zhong W Z, Yan H H, Chen K N, et al. Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial [J]. Signal Transduct Target Ther. 2023;8(1):76.","journal-title":"Signal Transduct Target Ther"},{"issue":"25","key":"4070_CR62","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","volume":"362","author":"M MAEMONDO","year":"2010","unstructured":"Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR [J]. N Engl J Med. 2010;362(25):2380\u20138.","journal-title":"N Engl J Med"},{"issue":"2","key":"4070_CR63","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC SORIA","year":"2018","unstructured":"Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-Mutated advanced Non-Small-Cell lung cancer [J]. N Engl J Med. 2018;378(2):113\u201325.","journal-title":"N Engl J Med"},{"issue":"2","key":"4070_CR64","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1056\/NEJMe1714580","volume":"378","author":"S Popat","year":"2018","unstructured":"Popat S. Osimertinib as First-Line treatment in EGFR-Mutated Non-Small-Cell lung cancer [J]. N Engl J Med. 2018;378(2):192\u20133.","journal-title":"N Engl J Med"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-04070-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-025-04070-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-04070-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T12:03:11Z","timestamp":1762171391000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-025-04070-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4070"],"URL":"https:\/\/doi.org\/10.1186\/s12957-025-04070-z","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"assertion":[{"value":"4 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All experiments in this study did not involve human or animal tissues, thus ethical approval was not required. All cell experiments were conducted in accordance with standard laboratory protocols, ensuring the experiments were performed properly and safely.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"415"}}